Literature DB >> 15066868

Neonate characteristics after maternal use of antidepressants in late pregnancy.

Bengt Källén1.   

Abstract

BACKGROUND: Exposure to antidepressants during the third trimester of pregnancy has been associated with an increased risk for adverse birth outcomes, including preterm birth, respiratory distress, and hypoglycemia.
OBJECTIVE: To investigate neonatal outcomes in 997 infants (987 mothers) after maternal use of antidepressants based on prospectively recorded information in antenatal care documents.
RESULTS: An increased risk for preterm birth (odds ratio [OR], 1.96) and low birth weight (OR, 1.98) was verified, but the gestational week-specific birth weight was increased notably after exposure to tricyclic antidepressants. An increased risk for a low Apgar score (OR, 2.33), respiratory distress (OR, 2.21), neonatal convulsions (OR,1.90), and hypoglycemia (OR, 1.62) was found, the latter especially after exposure to tricyclic drugs, but no significant effect on the frequency of neonatal jaundice was seen (OR, 1.13). Most effects seemed not to be selective serotonin reuptake inhibitor drug specific, and outcomes after exposure to paroxetine hydrochloride were not worse than after exposure to other selective serotonin reuptake inhibitors.
CONCLUSIONS: Neonatal effects after maternal use of antidepressant drugs during late pregnancy were seen. Selective serotonin reuptake inhibitors may be the drugs of choice during pregnancy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15066868     DOI: 10.1001/archpedi.158.4.312

Source DB:  PubMed          Journal:  Arch Pediatr Adolesc Med        ISSN: 1072-4710


  69 in total

1.  A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction.

Authors:  Nancy K Grote; Jeffrey A Bridge; Amelia R Gavin; Jennifer L Melville; Satish Iyengar; Wayne J Katon
Journal:  Arch Gen Psychiatry       Date:  2010-10

Review 2.  Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: a focus on methodological issues.

Authors:  Luke E Grzeskowiak; Andrew L Gilbert; Janna L Morrison
Journal:  Drug Saf       Date:  2011-11-01       Impact factor: 5.606

Review 3.  Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates?

Authors:  Gideon Koren; Doreen Matsui; Adrienne Einarson; David Knoppert; Meir Steiner
Journal:  CMAJ       Date:  2005-05-24       Impact factor: 8.262

4.  Selective serotonin reuptake inhibitor use and risk of gestational hypertension.

Authors:  Sengwee Toh; Allen A Mitchell; Carol Louik; Martha M Werler; Christina D Chambers; Sonia Hernández-Díaz
Journal:  Am J Psychiatry       Date:  2009-01-02       Impact factor: 18.112

5.  The use of central nervous system active drugs during pregnancy.

Authors:  Bengt Källén; Natalia Borg; Margareta Reis
Journal:  Pharmaceuticals (Basel)       Date:  2013-10-10

Review 6.  Fetal effects of psychoactive drugs.

Authors:  Amy L Salisbury; Kathryn L Ponder; James F Padbury; Barry M Lester
Journal:  Clin Perinatol       Date:  2009-09       Impact factor: 3.430

7.  Gene-class analysis of expression patterns induced by psychoactive pharmaceutical exposure in fathead minnow (Pimephales promelas) indicates induction of neuronal systems.

Authors:  Michael A Thomas; Parag P Joshi; Rebecca D Klaper
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2011-06-06       Impact factor: 3.228

8.  A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight.

Authors:  Hsiang Huang; Shane Coleman; Jeffrey A Bridge; Kimberly Yonkers; Wayne Katon
Journal:  Gen Hosp Psychiatry       Date:  2013-10-02       Impact factor: 3.238

9.  The effects of maternal depression and use of antidepressants during pregnancy on risk of a child small for gestational age.

Authors:  Hans Mørch Jensen; Randi Grøn; Ojvind Lidegaard; Lars Henning Pedersen; Per Kragh Andersen; Lars Vedel Kessing
Journal:  Psychopharmacology (Berl)       Date:  2013-03-02       Impact factor: 4.530

10.  Association of Panic Disorder, Generalized Anxiety Disorder, and Benzodiazepine Treatment During Pregnancy With Risk of Adverse Birth Outcomes.

Authors:  Kimberly Ann Yonkers; Kathryn Gilstad-Hayden; Ariadna Forray; Heather S Lipkind
Journal:  JAMA Psychiatry       Date:  2017-11-01       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.